SNN - Smith & Nephew plc
NYSE
->
Healthcare
->
Medical Devices
Watford,
United Kingdom
Type: Equity
SNN price evolution
SNN
| (in millions $) | 31 Jan 2024 | 1 Aug 2023 | 31 Jan 2023 | 1 Aug 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $302 | $190 | $350 | $516 |
| Short term investments | ||||
| Net receivables | $1333 | $1277 | $1301 | $1253 |
| Inventory | $2395 | $2411 | $2205 | $1990 |
| Total current assets | $4030 | $3878 | $3856 | $3759 |
| Long term investments | ||||
| Property, plant & equipment | $1470 | $1421 | $1455 | $1460 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $9987 | $9844 | $9966 | $10105 |
| Current liabilities | ||||
| Accounts payable | $1055 | $955 | $1098 | $1013 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2271 | $1767 | $1715 | $2117 |
| Long term debt | $2319 | $2633 | $2712 | $2281 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4770 | $4611 | $4707 | $4710 |
| Shareholders' equity | ||||
| Retained earnings | $4521 | $4550 | $4587 | $4711 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $302 | $350 | $1290 | $1762 |
| Short term investments | ||||
| Net receivables | $1333 | $1301 | $1172 | $1106 |
| Inventory | $2395 | $2205 | $1844 | $1691 |
| Total current assets | $4030 | $3856 | $4424 | $4664 |
| Long term investments | $6110 | $198 | $117 | |
| Property, plant & equipment | $1470 | $1455 | $1513 | $1449 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $9987 | $9966 | $10920 | $11012 |
| Current liabilities | ||||
| Accounts payable | $1055 | $1098 | $1043 | $891 |
| Deferred revenue | ||||
| Short long term debt | $160 | $430 | $268 | |
| Total current liabilities | $2271 | $1715 | $2131 | $1688 |
| Long term debt | $2319 | $2712 | $2707 | $3207 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4770 | $4707 | $5352 | $5733 |
| Shareholders' equity | ||||
| Retained earnings | $4521 | $4587 | $5225 | $4958 |
| Other shareholder equity | -$328 | -$311 | ||
| Total shareholder equity | $5259 | $5568 | $5279 | |
| (in millions $) | 31 Jan 2024 | 1 Aug 2023 | 31 Jan 2023 | 1 Aug 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2815 | $2734 | $2615 | $2600 |
| Cost of revenue | ||||
| Gross Profit | $1921 | $1898 | $1848 | $1827 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1473 | $1583 | $1549 | $1492 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$12 | $39 | -$15 | $27 |
| Interest expense | -$64 | -$64 | -$174 | -$33 |
| Net income | ||||
| Net income | $91 | $172 | $46 | $177 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 6 Mar 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5549 | $5215 | $5212 | $4560 |
| Cost of revenue | $1540 | $1514 | $1381 | |
| Gross Profit | $3819 | $3675 | $3698 | $3179 |
| Operating activities | ||||
| Research & development | $345 | $349 | $307 | |
| Selling, general & administrative | $2880 | $2637 | $2439 | |
| Total operating expenses | $3056 | $4906 | $4500 | $4127 |
| Operating income | $309 | $712 | $433 | |
| Income from continuing operations | ||||
| EBIT | $309 | $712 | $433 | |
| Income tax expense | $27 | $12 | $62 | -$202 |
| Interest expense | -$128 | -$80 | -$62 | |
| Net income | ||||
| Net income | $263 | $223 | $524 | $448 |
| Income (for common shares) | $223 | $524 | $448 | |
| (in millions $) | 31 Jan 2024 | 1 Aug 2023 | 31 Jan 2023 | 1 Aug 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$448 | -$182 | -$472 | -$268 |
| Financing activities | ||||
| Dividends paid | -$327 | -$201 | -$327 | -$202 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$200 | -$86 | -$926 | -$704 |
| Effect of exchange rate | -$4 | -$6 | -$11 | -$8 |
| Change in cash and equivalents | -$44 | -$161 | -$941 | -$773 |
| (in millions $) | 31 Jan 2024 | 6 Mar 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $223 | $524 | $448 | |
| Operating activities | ||||
| Depreciation | $617 | $522 | $501 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $468 | $877 | $935 | |
| Investing activities | ||||
| Capital expenditures | -$358 | -$408 | -$443 | |
| Investments | $2 | $7 | ||
| Total cash flows from investing | -$448 | -$472 | -$691 | -$606 |
| Financing activities | ||||
| Dividends paid | -$327 | -$329 | -$328 | |
| Sale and purchase of stock | ||||
| Net borrowings | $2522 | -$326 | $1490 | |
| Total cash flows from financing | -$200 | -$926 | -$645 | $1164 |
| Effect of exchange rate | -$4 | -$7 | $1 | |
| Change in cash and equivalents | -$44 | -$940 | -$466 | $1494 |
News
Fundamentals
| Market cap | $10.49B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 437.07M |
| Revenue | $10.76B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $486.00M |
| Revenue Q/Q | 116.54% |
| Revenue Y/Y | 106.48% |
| P/E ratio | 21.59 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.97 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.69 |
| EPS | $1.11 |
|---|---|
| ROA | 4.87% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.77 |
| Quick ratio | 0.72 |